A detailed history of Geode Capital Management, LLC transactions in I Mab stock. As of the latest transaction made, Geode Capital Management, LLC holds 22,037 shares of IMAB stock, worth $19,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,037
Previous 34,347 35.84%
Holding current value
$19,833
Previous $57,000 52.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.03 - $1.72 $12,679 - $21,173
-12,310 Reduced 35.84%
22,037 $27,000
Q3 2023

Nov 13, 2023

SELL
$1.18 - $3.06 $251 - $651
-213 Reduced 0.62%
34,347 $45,000
Q2 2023

Aug 11, 2023

SELL
$2.95 - $3.85 $613 - $800
-208 Reduced 0.6%
34,560 $103,000
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $58,510 - $140,387
-18,997 Reduced 35.33%
34,768 $120,000
Q4 2022

Feb 13, 2023

BUY
$3.22 - $4.86 $76,813 - $115,935
23,855 Added 79.76%
53,765 $224,000
Q3 2022

Nov 14, 2022

SELL
$4.01 - $12.34 $54,515 - $167,762
-13,595 Reduced 31.25%
29,910 $119,000
Q2 2022

Aug 12, 2022

SELL
$8.27 - $18.43 $1.14 Million - $2.54 Million
-137,809 Reduced 76.01%
43,505 $491,000
Q1 2022

May 13, 2022

BUY
$12.54 - $46.93 $75,453 - $282,377
6,017 Added 3.43%
181,314 $2.93 Million
Q4 2021

Feb 11, 2022

BUY
$45.28 - $74.5 $823,960 - $1.36 Million
18,197 Added 11.58%
175,297 $8.25 Million
Q3 2021

Nov 12, 2021

BUY
$57.18 - $84.43 $1.03 Million - $1.52 Million
18,009 Added 12.95%
157,100 $11.3 Million
Q2 2021

Aug 13, 2021

BUY
$47.86 - $83.95 $6.15 Million - $10.8 Million
128,599 Added 1225.69%
139,091 $11.6 Million
Q4 2020

Feb 12, 2021

BUY
$32.94 - $47.15 $169,772 - $243,011
5,154 Added 96.55%
10,492 $494,000
Q3 2020

Nov 13, 2020

BUY
$27.46 - $47.03 $146,581 - $251,046
5,338 New
5,338 $251,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.